Organon and Co

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

491

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 8 drugs with upcoming expirations

Activity

Key Events

Mar 25, 2026TrialA 5-year, Double-blind, Randomized, Placebo-controlled Extension Study to Examine the Long-term Safety and Efficacy of Oral Alendronate in Postmenopausal Women Who Previously Received Alendronate in Conjunction With the Fracture Intervention Trial

Feb 26, 2026FDARizafilm — RIZAFILM

Dec 29, 2025TrialA Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

Mar 13, 2025FDACozaar — ARBLI

Jul 26, 2023TrialEffectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients

Mar 13, 2023TrialA Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Region

Dec 27, 2022TrialA Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis

Oct 25, 2022TrialA Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain

4 more events

May 23, 2022FDAVtama — VTAMA

Feb 17, 2022TrialContraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive

Dec 2, 2021TrialTapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects

Nov 15, 2021TrialMaximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

17 patent groups across drugs · Source: FDA Orange Book

DrugExpires

ZetiaOct 30, 2025 ZetiaApr 30, 2026 ImplanonAug 28, 2026 Rayaldee3 patentsFeb 2, 2027 ZocorApr 26, 2027 Implanon2 patentsMay 31, 2027 Rayaldee8 patentsApr 25, 2028 ZocorFeb 23, 2030

9 more

ImplanonJul 28, 2030 RayaldeeSep 7, 2030 FosamaxDec 5, 2031 Rayaldee4 patentsMar 14, 2034 RizafilmJul 30, 2034 Vtama6 patentsMay 19, 2036 Vtama2 patentsNov 13, 2038 Vtama4 patentsNov 13, 2039 Cozaar3 patentsOct 7, 2041

Regulatory

Regulatory Timeline

20002 events

FDASep 20

OVIDREL — OVIDREL

Application BLA021149 (BLA)

FDAMar 3

Singulair — SINGULAIR

Application NDA020830 (NDA)

20012 events

FDADec 21

Clarinex — CLARINEX

Application NDA021165 (NDA)

FDAJan 12

Remeron — REMERON SOLTAB

Application NDA021208 (NDA)

20022 events

FDAOct 25

Zetia — ZETIA

Application NDA021445 (NDA)

FDAJul 26

Singulair — SINGULAIR

Application NDA021409 (NDA)

20031 event

FDASep 17

Fosamax — FOSAMAX

Application NDA021575 (NDA)

20041 event

FDASep 1

Clarinex — CLARINEX

Application NDA021300 (NDA)

20051 event

FDAJul 14

Clarinex — CLARINEX

Application NDA021312 (NDA)

20061 event

FDAJul 17

Implanon — IMPLANON

Application NDA021529 (NDA)

20071 event

FDAOct 9

Zocor — SIMVASTATIN

Application NDA021961 (NDA)

20121 event

FDAMar 12

Fosamax — BINOSTO

Application NDA202344 (NDA)

20162 events

FDAJun 17

Rayaldee — RAYALDEE

Application NDA208010 (NDA)

FDAApr 21

Zocor — FLOLIPID

Application NDA206679 (NDA)

20171 event

FDAApr 21

Remicade — RENFLEXIS

Application BLA761054 (BLA)

20181 event

FDADec 14

Herceptin — HERZUMA

Application BLA761091 (BLA)

20191 event

FDAJan 18

Herceptin — ONTRUZANT

Application BLA761100 (BLA)

20221 event

FDAMay 23

Vtama — VTAMA

Application NDA215272 (NDA)

20251 event

FDAMar 13

Cozaar — ARBLI

Application NDA218772 (NDA)

20261 event

FDAFeb 26

Rizafilm — RIZAFILM

Application NDA205394 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)